Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001332784 XXXXXXXX LIVE 5 Common Stock, par value $0.01 per share 12/08/2025 false 0001567892 G5890A102 Keenova Therapeutics plc College Business & Technology Park Cruiserath, Blanchardstown Dublin 15 L2 D15 TX2V James Kasmarcik 203-542-4200 Silver Point Capital, L.P. 2 Greenwich Plaza, Suite 1 Greenwich CT 06830 0001332784 N Silver Point Capital, L.P. b OO N DE 0 4702714 0 4702714 4702714 N 11.9 IA PN 0001029625 N Edward A. Mule b OO N X1 0 4702714 0 4702714 4702714 N 11.9 IN 0001382617 N Robert J. O'Shea b OO N X1 0 4702714 0 4702714 4702714 N 11.9 IN Common Stock, par value $0.01 per share Keenova Therapeutics plc College Business & Technology Park Cruiserath, Blanchardstown Dublin 15 L2 D15 TX2V This Amendment No. 5 (the "Amendment") amends the statement on Schedule 13D originally filed by the Reporting Persons on November 24, 2023, as amended by Amendment No. 1 filed by the Reporting Persons on January 22, 2024, Amendment No. 2 filed by the Reporting Persons on July 8, 2024, Amendment No. 3 filed by the Reporting Persons on March 18, 2025, and Amendment No. 4 filed by the Reporting Persons on November 5, 2025 (as amended, the "Schedule 13D"). Capitalized terms used but not otherwise defined in this Amendment shall have the meanings ascribed to such terms in the Schedule 13D. Except as otherwise provided herein, each Item of the Schedule 13D remains unchanged. Item 3 of the Schedule 13D is hereby supplemented as follows: The source of funds used in the acquisitions reported in Item 5 was working capital of the Reporting Persons. The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Amendment are incorporated herein by reference. The Reporting Persons currently beneficially own 4,702,714 shares of Common Stock, representing 11.9% of the shares of Common Stock outstanding. As reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2025, as of November 7, 2025, there were 39,526,162 shares of Common Stock issued and outstanding. The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Amendment are incorporated herein by reference. The following sets forth all transactions in the Common Stock effected by the Reporting Persons since the Reporting Persons' most recent filing on Schedule 13D with respect to the Common Stock: On December 8, 2025, the Reporting Persons purchased 130,974 shares of Common Stock at a price per share of $88.75 in the open market through brokers. On November 19, 2025, the Reporting Persons purchased 42,000 shares of Common Stock at a price per share of $88.875 in the open market through brokers. On November 17, 2025, the Reporting Persons purchased 26,000 shares of Common Stock at a price per share of $88.875 in the open market through brokers. On November 10, 2025, the Reporting Persons purchased 290,000 shares of Common Stock at a price per share of $93.75 in the open market through brokers. Other than as disclosed in Item 4, no person other than the Reporting Persons are known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Common Stock held by the Reporting Persons. Not applicable. Exhibit No. Description 1 Joint Filing Agreement, dated as of December 10, 2025, by and among the Reporting Persons 2 Power of Attorney of Robert J. O'Shea and Edward A. Mule (incorporated here by reference to Schedule 13G filed by Silver Point Capital, L.P., Edward A. Mule and Robert J. O'Shea with the Securities and Exchange Commission on February 16, 2016 relating to TopBuild Corp.) Silver Point Capital, L.P. /s/ Steven Weiser Steven Weiser/Authorized Signatory 12/10/2025 Edward A. Mule /s/ Steven Weiser Steven Weiser/Attorney-in-fact 12/10/2025 Robert J. O'Shea /s/ Steven Weiser Steven Weiser/Attorney-in-fact 12/10/2025